Novel role for the incretins in blood pressure regulation

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 5, 2012, Pages 463-468

  Yerram, Preethi ^a   Whaley Connell, Adam ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

dipeptidyl peptidase 4; glucagon like peptide 1; incretin; incretin axis

Indexed keywords

CYCLIC AMP; CYCLIC GMP; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SODIUM; VILDAGLIPTIN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; DRUG MECHANISM; FOOD INTAKE; GLYCEMIC CONTROL; HEART MUSCLE CELL; HEART RATE; HUMAN; HYPERTENSION; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN TREATMENT; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; REVIEW; SODIUM URINE LEVEL; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERTENSION; INCRETINS;

EID: 84865410956     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328356bccd     Document Type: Review

References (53)

1. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902; 28:325-353.
2. Moore B, Edie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1906; 1:28-38.
3. Zunz E, La Barre J. Contributiona a l'etude des variations physiologiques de la secretion interne du pancreas: relations entre les secretions externe et interne du pancreas. Arch Int Physiol Biochim 1929; 31:20-44.
4. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24:1076-1082.
5. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964; 2:20-21.
6. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010; 1 (1/2):8-23.
7. Creutzfeldt W. The [pre] history of the incretin concept. Regul Pept 2005; 128:87-91.
8. Brown JC, Dryburgh JR. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 1971; 49:867-872.
9. Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 1970; 209:57-64.
10. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37:826-828.
11. Ebert R, Unger H, Creutzfeldt W. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 1983; 24:449-454. (Pubitemid 13057382)
12. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28:704-707. (Pubitemid 16226411)
13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157. (Pubitemid 46711096)
14. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-165.
15. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33:187-215.
16. Thorens B, Porret A, Bü hler L, et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993; 42:1678-1682. (Pubitemid 23318127)
17. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137:2968-2978. (Pubitemid 26192194)
18. Abu-Hamdah R, Rabiee A, Meneilly GS, et al. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009; 94:1843-1852.
19. Holz GGt, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361:362-365. (Pubitemid 23041630)
20. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulindependent) diabetic patients. Diabetologia 1993; 36:741-744. (Pubitemid 23218642)
21. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008; 51:2263-2270.
22. Kulkarni RN. GIP: no longer the neglected incretin twin? Sci Transl Med 2010; 2:49s47.
23. Usdin TB, Mezey E, Button DC, et al. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133:2861-2870. (Pubitemid 24000747)
24. Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens 2012; 6:163-168.
25. Nauck MA, Bü sing M, Orskov C, et al. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol 1993; 30:39-45. (Pubitemid 23286367)
26. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124 (1 Suppl):S3-S18.
27. Wang B, Ni Y, Zhong J, Sun F. Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension. J Diabetes 2012; 4:22-29.
28. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:E1209-E1215. (Pubitemid 39491964)
29. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109:962-965. (Pubitemid 38282847)
30. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125 (1-3):173-177. (Pubitemid 39593722)
31. Golpon HA, Puechner A, Welte T, et al. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102 (2-3):81-86. (Pubitemid 33135568)
32. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008; 117:2340-2350. (Pubitemid 351653542)
33. Tanaka T, Nangaku M, Nishiyama A. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. CurrOpin Nephrol Hypertens 2011; 20:476-481.
34. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89:3055-3061. (Pubitemid 38766408)
35. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagonlike peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21:1125-1135. (Pubitemid 36667866)
36. Hirata K, Kume S, Araki S, et al. Exendin-4 has an antihypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009; 380: 44-49.
37. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 2007; 141 (1-3):120-128. (Pubitemid 46482693)
38. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110:43-52. (Pubitemid 34743464)
39. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010; 23:334-339.
40. Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293:E1289-E1295. (Pubitemid 350106596)
41. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30:1608-1610. (Pubitemid 46871185)
42. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22:1137-1143. (Pubitemid 29293967)
43. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48:592-598. (Pubitemid 351503521)
44. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagonlike peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4Met+TZD). Diabetes Care 2009; 32:1224-1230.
45. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33:1300-1303.
46. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009; 373:473-481.
47. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26:268-278.
48. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32:84-90.
49. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375:1447-1456.
50. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52:2046-2055.
51. Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223:133-135.
52. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11:611-622.
53. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376:431-439.